Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KAN-101 in celiac disease
NCT06001177Phase 2Completed
- Sponsor
- Anokion
- Start
- Dec 2023
- Primary completion
- Jan 2025
- Modality
- Small Molecules, Modified Peptides
- Countries
- 8
01
Overview
A Phase 2 trial of KAN-101 in celiac disease, sponsored by Anokion. Started Dec 2023; status: completed.
02
Drugs
KAN-101
03
Conditions
celiac disease
Beyond the preview
Go deeper on NCT06001177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06001177.